...
首页> 外文期刊>European review for medical and pharmacological sciences. >Preparation of microencapsulated VEGF gene-modified human umbilical cord mesenchymal stem cells and in vitro culture
【24h】

Preparation of microencapsulated VEGF gene-modified human umbilical cord mesenchymal stem cells and in vitro culture

机译:微囊化VEGF基因修饰的人脐带间充质干细胞的制备及体外培养

获取原文

摘要

BACKGROUND AND OBJECTIVES: The application of microencapsulated stem cells has been shown to have many advantages in various fields of medical research. However, optimal modes for preparation of microencapsulate stem cells need to be improved, and expression and release of products of microencapsulated gene modified stem cells need to be studied in vitro. AIM OF THE STUDY: To explore the optimal parameters when preparing microencapsulated stem cells, and to investigate the effect of microencapsulation on growth, secretion, and metabolism of genetically modified human Umbilical Cord Mesenchymal Stem Cells (hUCMSCs). MATERIALS AND METHODS: In this study, the parameters of preparation were regulated by observing the microcapsule shape and size. Live/dead cell viability kits and fluorescein isothiocyanate-labeled dextrans (FD) were used to detect the microencapsulated cell viability, and the permeability of microcapsules, respectively. Vascular endothelial growth factor (VEGF) production in the supernatant of microencapsulated and non-microencapsulated VEGF gene-modified hUCMSCs cultures was measured by ELISA. RESULTS: The optimal parameters of preparing microcapsules were regulated as followed: bolus velocity was 6 ml/h, and airflow velocity was 3 L/min. The morphology of microcapsules was a spherical structure with a diameter of 450 ± 30 μm. More than 90% of the cells were viable after 21 days of culture. Low and middle molecular weight FD was able to pass through the microcapsules; however, high molecular weight FD was not. Also, the VEGF concentration in microencapsulated and non-microencapsulated cell culture supernatants exhibited no significant difference at each time point. CONCLUSIONS: Microencapsulated stem cells can be ideally prepared via specifically regulated preparation. Lastly, microencapsulation does not alter growth, secretion, and metabolism of the genetically modified hUCMSCs.
机译:背景与目的:微囊干细胞的应用已被证明在医学研究的各个领域具有许多优势。然而,需要改进用于制备微囊干细胞的最佳模式,并且需要在体外​​研究微囊基因修饰的干细胞产物的表达和释放。研究目的:探讨制备微囊化干细胞时的最佳参数,并研究微囊化对转基因人脐带间充质干细胞(hUCMSCs)生长,分泌和代谢的影响。材料与方法:本研究通过观察微胶囊的形状和大小来调节制备参数。使用活/死细胞活力试剂盒和异硫氰酸荧光素标记的右旋糖酐(FD)分别检测微囊化的细胞活力和微胶囊的通透性。通过ELISA测量微囊化和非微囊化VEGF基因修饰的hUCMSCs培养物的上清液中的血管内皮生长因子(VEGF)的产生。结果:制备微胶囊的最佳参数如下:推注速度为6 ml / h,气流速度为3 L / min。微胶囊的形态是直径为450±30μm的球形结构。培养21天后,超过90%的细胞存活。中低分子量FD能够通过微囊。然而,高分子量FD却不是。而且,微囊化和非微囊化的细胞培养上清液中的VEGF浓度在每个时间点均没有显示出显着差异。结论:理想的方法是通过特殊调节的方法制备微囊化的干细胞。最后,微囊化不会改变基因修饰的hUCMSC的生长,分泌和代谢。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号